CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO

Their core work

CRO Aviano is Italy's National Cancer Institute, a specialized clinical research centre focused on oncology diagnosis, treatment, and translational research. In H2020, they contributed clinical expertise in cancer therapeutics — from ovarian cancer characterization (HERCULES) to point-of-care chemotherapy drug monitoring (DiaChemo) and pharmacogenomics for personalized treatment (U-PGx). Their work sits at the intersection of clinical oncology and precision medicine, bringing patient cohorts, biobank access, and clinical trial infrastructure to European consortia.

What they specialise in

How they've shifted over time

All three projects started within a narrow window (2015–2016), making it difficult to identify a clear temporal shift in focus. The portfolio consistently centres on precision oncology — from drug monitoring to pharmacogenomics to cancer subtype characterization. With no projects after 2016, it is unclear whether CRO Aviano continued H2020 participation under different entities or shifted focus areas in later calls.

Their trajectory points toward personalized cancer treatment — pharmacogenomics and biomarker-driven therapy selection — which aligns with broader EU health research priorities.

How they like to work

CRO Aviano consistently joins consortia as a clinical partner rather than leading them — zero coordinator roles across all three projects, with one involvement as a third party. Their 39 unique partners across 12 countries suggest they are sought after as a specialist clinical site contributing patient data, biosamples, and oncology expertise. They function as a trusted clinical node in large research consortia rather than a project initiator.

CRO Aviano has collaborated with 39 distinct partners across 12 countries, indicating a well-connected European network for a non-coordinating institute. Their partnerships likely span university hospitals, genomics centres, and medtech developers across Western and Southern Europe.

What sets them apart

As Italy's dedicated national cancer research institute, CRO Aviano offers something most university hospitals cannot: a fully oncology-focused clinical and research environment with deep patient cohorts and biobanking infrastructure. Their participation across diagnostics (DiaChemo), genomics (U-PGx), and cancer biology (HERCULES) shows versatility within the oncology domain. For consortium builders, they represent a reliable Italian clinical site with proven EU project experience and no competing coordination ambitions.

Highlights from their portfolio

• U-PGx
  Largest funded project (EUR 875K) focused on ubiquitous pharmacogenomics — a flagship effort to bring personalized drug prescribing into routine clinical practice across Europe.
• DiaChemo
  Applied microfluidics to real-time chemotherapy drug monitoring, bridging medtech device development with clinical oncology needs.
• HERCULES
  Targeted high-grade serous ovarian cancer with combinatorial treatment strategies — CRO participated as a third party, suggesting specialized biobank or patient cohort contribution.